NASDAQ:PYXS

Pyxis Oncology Q2 2025 Earnings Results & Report

Pyxis Oncology logo
$1.44 +0.03 (+2.13%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.53%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pyxis Oncology beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.30 versus the -$0.36 consensus estimate, while revenue was $2.82 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Pyxis Oncology EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Pyxis Oncology Revenue Results

Actual Revenue
$2.82 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pyxis Oncology Q2 2025 Earnings FAQ

Pyxis Oncology (NASDAQ:PYXS) reported earnings of -$0.30 per share for Q2 2025, beating the consensus estimate of -$0.36. The report was announced on Thursday, August 14, 2025.

Pyxis Oncology reported revenue of $2.82 million for Q2 2025.

Pyxis Oncology Earnings Headlines

Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $7.00
See More Pyxis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email.

About Pyxis Oncology

Pyxis Oncology (NASDAQ:PYXS) is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue.

The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.

Founded in 2019 and based in Boston, Massachusetts, Pyxis Oncology was co-founded by Lara Sullivan, who has served as its president and chief executive officer. The company is focused on developing its therapies and does not have marketed products.

View Pyxis Oncology Profile